Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Other Non-Current Assets (2017 - 2025)

Cue Biopharma's Other Non-Current Assets history spans 9 years, with the latest figure at $667000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 517.59% year-over-year to $667000.0; the TTM value through Sep 2025 reached $667000.0, up 517.59%, while the annual FY2024 figure was $152000.0, 0.66% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $667000.0 at Cue Biopharma, down from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $3.1 million in Q4 2022 and bottomed at $108000.0 in Q3 2024.
  • The 5-year median for Other Non-Current Assets is $150000.0 (2021), against an average of $553210.5.
  • The largest annual shift saw Other Non-Current Assets soared 1977.33% in 2022 before it crashed 95.15% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $150000.0 in 2021, then skyrocketed by 1977.33% to $3.1 million in 2022, then plummeted by 95.15% to $151000.0 in 2023, then increased by 0.66% to $152000.0 in 2024, then soared by 338.82% to $667000.0 in 2025.
  • Per Business Quant, the three most recent readings for CUE's Other Non-Current Assets are $667000.0 (Q3 2025), $2.0 million (Q2 2025), and $153000.0 (Q1 2025).